CurrentAnthemPolicy CC-0076

Nulojix (belatacept) — Kidney transplant prophylaxis coverage criteria

Clinical criteria governing prior authorization and medical necessity for Nulojix (belatacept) when used to prevent organ rejection in adult kidney transplant recipients; applies to providers submitting requests under the payer's medical benefit.

Policy Summary

PayerAnthem

PolicyNulojix (belatacept) — Kidney transplant prophylaxis coverage criteria

Policy CodePolicy CC-0076

Change TypeReviewed — no material changes

Effective Date07/23/2025

Next Review DateJun 9, 2026

Key ActionObtain prior authorization and document adult kidney transplant status and EBV seropositivity with planned combination therapy at initiation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

EBV seropositiveEligibility requirement

Required at initiationCombination therapy

J0485Billing code

Kidney onlyOrgan limitation

PTLD riskSafety warning

Coverage Criteria for Nulojix (belatacept)

Covered when ALL of the following are met

Requests for Nulojix (belatacept) may be approved if the following criteria are met:

Initial and ongoing coverage criteria: I. Individual is an adult using for prevention of organ rejection in kidney transplant; AND II. Individual is Epstein-Barr virus (EBV) seropositive; AND III. If initiating therapy, Nulojix (belatacept) is used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids.

All three conditions must be met for approval.

Requests for Nulojix (belatacept) may be approved only when all of the following are met: the individual is an adult receiving a kidney transplant for prevention of organ rejection; the individual is EBV seropositive (presence of IgG antibodies to viral capsid antigen [VCA] and EBV nuclear antigen [EBNA]); and if initiating therapy, Nulojix will be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. Use outside this scope — including prophylaxis for transplanted organs other than the kidney — is not established and is not covered.

Requests that do not meet the criteria above should be considered nonconforming and may be denied. Specifically, prior authorization will not be approved for individuals who are not adult kidney transplant recipients, who are EBV seronegative or have unknown EBV serostatus, or when Nulojix is requested for indications other than kidney transplant rejection prophylaxis. Additionally, use in liver transplant patients is not recommended due to increased risk of graft loss and death, and such requests should be denied or referred for exception review as appropriate.

Policy Summary

PayerAnthem

PolicyNulojix (belatacept) — Kidney transplant prophylaxis coverage criteria

Policy CodePolicy CC-0076

Change TypeReviewed — no material changes

Effective Date07/23/2025

Next Review DateJun 9, 2026

Key ActionObtain prior authorization and document adult kidney transplant status and EBV seropositivity with planned combination therapy at initiation.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Candidate Eligibility Criteria

Kidney transplant candidate criteria

Candidate eligibility for Nulojix use in transplant recipients:

Kidney transplant candidate: Adult recipient of a kidney transplant; EBV seropositive status confirmed; planned use consistent with labeled concomitant agents at initiation (basiliximab induction, mycophenolate mofetil, corticosteroids).

Nulojix is only indicated for EBV seropositive kidney transplant patients.

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for Nulojix (belatacept). Approval is contingent upon documented clinical criteria being met prior to initiation.

Affected product: Nulojix (belatacept, J0485)
Approval conditions: adult kidney transplant recipient; documented EBV seropositive status; initiation only in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids

Step Therapy

Step therapy is not required beyond the specified combination use at initiation. There is no requirement to fail alternate agents prior to approval when the initiation combination criteria are met.

No additional step therapy or prior failures required when used per initiation regimen
Combination therapy at initiation is mandatory for new starts

Documentation Required

Required Clinical Documentation

Documentation must include evidence supporting adult kidney transplant status and EBV seropositivity prior to approval.

Clinical documentation: operative report or transplant discharge summary confirming kidney transplant
Laboratory documentation: EBV serology demonstrating IgG antibodies to VCA and EBNA (positive)
Medication plan: documentation that belatacept will be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids for initiation

Denial Risk

Triggers for Denial

Requests should be denied when key eligibility criteria are not met or excluded indications are present.

Patient is not an adult (pediatrics) — denial trigger
Transplant organ is not the kidney (e.g., liver, heart, lung) — denial trigger
EBV serostatus is negative or unknown — denial trigger
Initiation without documented combination regimen (basiliximab induction, mycophenolate mofetil, corticosteroids) — denial trigger
Use for indications other than prophylaxis of kidney transplant rejection — denial trigger

Billing and Diagnosis Codes

HCPCSHCPCS

J0485

Injection, belatacept, 1 mg [Nulojix]

ICD-10 DiagnosisICD-10

D82.3	Immunodeficiency following hereditary defective response to Epstein-Barr virus
Z48.22	Encounter for aftercare following kidney transplant
Z94.0	Kidney transplant status

EBV serostatus (definition and requirement)

DefinitionEBV seropositive is defined as presence of IgG antibodies to viral capsid antigen (VCA) and EBV nuclear antigen (EBNA).

Required test evidenceLaboratory documentation must demonstrate positive IgG to both VCA and EBNA prior to Nulojix use.

Clinical implicationPatients who are EBV seronegative or of unknown serostatus should not receive Nulojix due to increased PTLD risk.

Use in coverage determinationEBV seropositive status (IgG to VCA and EBNA) is a required eligibility threshold for prior authorization and medical necessity.

Use During and After Transplant

Nulojix (belatacept) infusion — HCPCS J0485

HCPCS codeJ0485 — Injection, belatacept, 1 mg (Nulojix).

Timing of useUsed beginning on the day of kidney transplantation (initial phase prior to implantation) and continued for maintenance thereafter.

Concomitant regimen at initiationWhen initiating therapy, Nulojix must be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids.

Indication limitationIndicated only for EBV seropositive adult kidney transplant recipients; not established for non-kidney transplants.

Contraindications and Safety Limits

Contraindications include individuals who are EBV seronegative or whose EBV serostatus is unknown, because these patients have an increased risk of post‑transplant lymphoproliferative disorder (PTLD) and should not receive Nulojix. Use of Nulojix in liver transplant recipients is not recommended due to documented increased risk of graft loss and death.

Evaluation and Pre-use Verification

Documentation Required

Evaluation requirements — verify EBV serostatus and kidney transplant status

Verify and document EBV serostatus prior to use (defined as presence of IgG antibodies to VCA and EBNA), confirm the patient is an adult kidney transplant recipient, and document the planned concomitant immunosuppressive regimen when initiating therapy.

EBV seropositive defined as IgG to VCA and EBNA.
Confirm planned use with basiliximab induction, mycophenolate mofetil, and corticosteroids for initiation.

Provider and Center Experience Requirements

Note

Center and prescriber requirements — experienced physicians and facility resources

Nulojix should be prescribed only by physicians experienced in immunosuppressive therapy and kidney transplant management; patients should be managed in facilities with adequate laboratory and supportive medical resources and the treating physician should have requisite follow‑up information.

Prescriber experience in immunosuppression and transplant care is required.
Facility must have adequate lab and supportive medical resources for monitoring.

Background on Belatacept (Nulojix)

Belatacept (Nulojix) is a selective T‑cell co‑stimulation blocker indicated to prevent organ rejection in EBV seropositive adults receiving a kidney transplant. It is administered beginning on the day of transplantation (prior to implantation) for the initial phase and continued as maintenance thereafter when clinically appropriate. Per labeling and safety guidance, Nulojix must be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids at initiation, and it is restricted to EBV seropositive patients because EBV seronegative recipients are at higher risk for developing PTLD. The drug carries a black box warning regarding PTLD and increased infection and malignancy risk, and should be prescribed and managed by clinicians experienced in immunosuppressive therapy with access to adequate laboratory and supportive resources.